Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Specific oculomotor deficits after amylobarbitone.

G Tedeschi, P R Bittencourt, A T Smith

    Psychopharmacology
    |January 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Malignant transformation in a cohort of patients with oral epithelial dysplasia.

    The British journal of oral & maxillofacial surgery·2021
    Same author

    Three changes to reduce the loss of dual degree trainees from OMFS national specialty selection in the UK: evidence based proposals.

    The British journal of oral & maxillofacial surgery·2021
    Same author

    Connectivity of the Cingulate Sulcus Visual Area (CSv) in Macaque Monkeys.

    Cerebral cortex (New York, N.Y. : 1991)·2020
    Same author

    Hyperexcitability of brain stem pathways in cerebral palsy.

    Journal of neurophysiology·2018
    Same author

    Measuring health-related benefit and quality of care in oral and maxillofacial surgery: British Association of Oral and Maxillofacial Surgeons Outcomes Project.

    The British journal of oral & maxillofacial surgery·2018
    Same author

    Errors in interpretation of neck levels in postoperative pathological specimens.

    The British journal of oral & maxillofacial surgery·2016
    Same journal

    Sotagliflozin pretreatment attenuates acute LPS-induced depression-like behavioral abnormalities and modulates the gut microbiota-immune-brain axis.

    Psychopharmacology·2026
    Same journal

    GlyT1 inhibition enhances working memory in the mouse TUNL task and normalizes NMDA antagonist-induced network activity.

    Psychopharmacology·2026
    Same journal

    Effects of repeated treatment with opioids that vary in mu opioid receptor efficacy on pain-depressed locomotor behavior in mice.

    Psychopharmacology·2026
    Same journal

    Cannabidiol in the anterior insular cortex attenuates chronic neuropathic pain and comorbid anxiety- and depression-like behaviors: involvement of CB<sub>1</sub> and 5-HT<sub>1A</sub> receptor signaling.

    Psychopharmacology·2026
    Same journal

    Fentanyl decreases arterial blood oxygen saturation more than furanylfentanyl in mice due to increased apnea.

    Psychopharmacology·2026
    Same journal

    Suicide attempt risk among patients receiving methylphenidate: a retrospective cohort study.

    Psychopharmacology·2026
    See all related articles

    Amylobarbitone sodium significantly impairs eye movement velocity, affecting both saccadic and smooth pursuit systems. This drug

    Area of Science:

    • Neuroscience
    • Pharmacology
    • Ophthalmology

    Background:

    • Amylobarbitone sodium is a sedative-hypnotic drug.
    • Its effects on ocular motor control are not fully understood.

    Purpose of the Study:

    • To investigate the impact of amylobarbitone sodium on saccadic and smooth pursuit eye movements.

    Main Methods:

    • Double-blind, randomized, placebo-controlled study.
    • Five healthy volunteers received 200 mg amylobarbitone sodium or placebo orally.
    • Eye movement parameters (saccadic peak velocity, duration, smooth pursuit velocity) were measured up to 6 hours post-administration.

    Main Results:

    • Amylobarbitone sodium significantly decreased saccadic and smooth pursuit eye velocity.

    Related Experiment Videos

  • Maximum impairment (25-29%) occurred at 2 hours post-dose.
  • Significant effects on saccadic peak velocity persisted for 6 hours.

    • Conclusions:

    • Therapeutic doses of amylobarbitone sodium impair the velocity generation capabilities of both saccadic and smooth pursuit eye movement systems.
    • Ocular motor function is sensitive to amylobarbitone sodium at clinically relevant doses.